"Effect of Vitamin E (α-Tocopherol) on Clinical Activity and Inflammation in Rheumatoid Arthritis"

Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexFemale
Age18+
SponsorUniversity of Guadalajara

About this trial

The objective of this clinical trial is to determine whether α-tocopherol (vitamin E) supplementation decreases inflammation and clinical activity in patients with rheumatoid arthritis (RA).The main questions to be answered are:

* Is supplementation with vitamin E (α-tocopherol) for one month associated with decreased clinical activity and inflammation in patients with RA?

Researchers will compare α-tocopherol with a placebo (a look-alike substance containing no active ingredient) to see if α-tocopherol effectively reduces inflammation and clinical activity in patients with rheumatoid arthritis.

Participants will:

* Take two capsules (one in the morning and one in the afternoon) of either α-tocopherol or placebo every day for a month. * Attend clinic visits at the start of the intervention (baseline) and at the end of the month for final check-ups and tests. * Keep a diary to record your symptoms and how often you take α-tocopherol or placebo.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Female sex

RA classification (ACR/EULAR 2010)

Early RA 2 years

Treatment with conventional synthetic FARMEs (Metrotexato, Hydroxychloroquine, Leflunomide, Sulfasalazina and their combinations)

Disqualifiers

Liver and kidney disease

Overlap syndrome

Coagulation disorders

Pregnancy

Trial design

Design model

Parallel

Treatments tested in this trial

  • Will take vitamin E 800mg/day

    Dietary supplement

    Patients with deficient vitamin E intake (\<15mg/day), who are treated with conventional synthetic FARMEs (Metrotexato, Hydroxychloroquine, Leflunomide, Sulfasalazina and their combinations) plus vitamin E 800mg/day.

  • Will take 200mg/day magnesium oxide placebo.

    Drug

    Patients with RA deficient in vitamin E intake (\<15mg/day) , who are treated with conventional synthetic FARMEs (Metrotexato, Hydroxychloroquine, Leflunomide, Sulfasalazina and their combinations) plus the consumption of magnesium oxide 200mg/day in placebo form.

Treatment groups

46 Participants
are divided into 2 treatment groups
Group A: Intervention groupActive comparator 1 intervention
Group B: Control groupPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Levels of vitamin E

Adequacy:12 and 20 µg/mL (27.9-46.4 µmol/L). Insufficiency: 5 and 12 µg/mL (11.6-27.9 µmol/L). Minor deficiency of: 5 µg/mL (11.6 µmol/L).

Time frame
Exchange measures: Baseline and 1 month.

Secondary outcomes

1

Twenty-four hour reminder "questionnaire" (Recommended Daily Intake of Vitamin E)

Twenty-four hour reminder: Will be done by the nutritionist, who will ask about the food consumed on the previous day to evaluate the quality of the diet and vitamin E consumption. The twenty-four hour reminder is a subjective method, retrospective, conducted through a face-to-face or telephone interview. This method is based on accurately remembering, describing and quantifying the food consumed one day before the consultation. All the patient's dietary intake throughout the day should be described in detail. \> 19 years old. 15 mg daily.

Time frame
Exchange measures: Baseline and 1 month.
2

Levels of: Proinflammatory cytokines ( IL-1β , IL-6 and TNF-α )

Units: pg/ml

Time frame
Exchange measures: Baseline and 1 month.
3

Antioxidant capacity: (DPPH, ABTS, FRAP and ORAC)

Units: μmol EQ trolox/μL sample

Time frame
Exchange measures: Baseline and 1 month.
4

Index DAS-28

Remission: \< 2.6 Low activity: 2.6 \<3.2 Moderate: 3.2 \< 5.1 High: 5.1

Time frame
Exchange measures: Baseline and 1 month.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Guadalajara

Lead sponsor

Hospital Civil de Guadalajara

Collaborator